Skip to main content
. 2018 Mar 23;2(6):681–690. doi: 10.1182/bloodadvances.2017012104

Table 2.

Patient outcomes

Patient Diagnosis Disease status at CD8+ TM cell infusion CD8+ TM cell dose, × 106 cells per kg 3-month response after CD8+ TM cell infusion 6-month response after CD8+ TM cell infusion Time from CD8+ TM cell infusion to death or last follow-up, d Status at last follow-up
1 AML CR2 1.0 CR2 CR 1057 Dead
2 AML Active disease 1.0 CR2 CR 591 Dead
3 AML CR3 1.0 CR3 CR 1328 Alive in CR
4 AML CR2 5.0 CR2 PD 430 Dead
5 CML CR3 5.0 CR3 CR 1069 Alive in CR
6 CLL Active disease 5.0 PD PD 168 Dead
7 AML Active disease 7.8 PD PD 128 Dead
8 AML Active disease 8.0 PD PD 151 Dead
9 NHL Active disease 10.0 PD PD 495 Alive with disease
10 NHL Active disease 5.2 SD PD 412 Alive with disease
11 AML CR2 10.0 CR2 CR 328 Alive in CR
12 AML CR3 7.7 CR3 PD 286 Alive with disease
13 NHL Active disease 10.0 SD PD 194 Dead
14 MM Active disease 10.0 PD PD 221 Alive with disease
15 ALL Active disease 10.0 PR PD 118 Alive with disease

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.